ChemoCentryx Inc said on Friday the U.S. health agency approved its lead drug for treating a rare, fatal autoimmune disease, sending the biopharmaceutical company's shares up by more than 70%.
cancer drug Rituxan, combined with daily administration of steroids, which can cause severe side effects.
The disease affects about 40,000 people in the United States, with about 4,000 new cases each year, according to the company.The drug had received mixed reviews from an expert panel to the U.S. Food and Drug Administration in May, with the committee's vote split equally on whether the efficacy data supported the drug's approval.
Following this meeting, the company submitted additional data in July for its marketing application for avacopan., giving it the commercialization rights in the United States, while Vifor has rights for the rest of the world. The drug was approved in Japan last month and the European regulatory body could give its nod by the end of this year.Reporting by Oishee Majumdar and Dania Nadeem in Bengaluru; Editing by Rashmi Aich and Anil D'SilvaSubscribe for our daily curated newsletter to receive the latest exclusive Reuters coverage delivered to your inbox.
France Dernières Nouvelles, France Actualités
Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.
21 Years After FDA Approval, Abortion Pill Is More Critical Than EverOn the 21st anniversary of FDA approval of the abortion pill, now is a good time to remember the courageous and tenacious people who fought for decades to make this life-saving medication possible.
Lire la suite »
COVID-19 live updates: Pfizer submits kids vaccine emergency use authorization request to FDAThe United States has been facing a COVID-19 surge as the more contagious delta variant continues to spread.
Lire la suite »
Pfizer seeks FDA authorization of Covid-19 vaccine for children ages 5 to 11Pfizer and BioNTech said Thursday they are seeking US Food and Drug Administration emergency use authorization from for their Covid-19 vaccine for children ages 5 to 11.
Lire la suite »
FDA still without a permanent leader as clock ticks down on acting headThe FDA is still without a permanent leader as the clock ticks down. Dr. Janet Woodcock is serving as the acting leader of the agency, but legally she can only stay on as acting head through November 15, unless a permanent commissioner is nominated.
Lire la suite »